Multiple Sclerosis Journal最新文献

{"title":"Considerations for family planning in adolescent and young adults with multiple sclerosis.","authors":"Kristen M Krysko","doi":"10.1177/13524585241303481","DOIUrl":"https://doi.org/10.1177/13524585241303481","url":null,"abstract":"","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"13524585241303481"},"PeriodicalIF":4.8,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142792089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imaging the Choroid Plexus.","authors":"Niels Bergsland, Michael G Dwyer, Robert Zivadinov","doi":"10.1177/13524585241292965","DOIUrl":"10.1177/13524585241292965","url":null,"abstract":"<p><p>The choroid plexus (CP), a highly vascularized structure within the ventricles of the brain, has come under increased scrutiny over the last several years as potentially having a role in the pathophysiology of multiple sclerosis (MS). Originally consider as being only responsible for the production of cerebrospinal fluid, it is now widely recognized that the CP is also involved in immunosurveillance and immune cell trafficking. Histopathology studies have found several immunological changes in donor tissue, including the accumulation of inflammatory cells. These findings have been corroborated by animal studies combining immunohistopathology and magnetic resonance imaging (MRI), showing dynamic changes in CP volume that track immune cell infiltration into the CP itself. Subsequent in vivo studies in persons with MS using MRI have suggested that while CP volume increases very early in the disease, CP inflammation continues to have a role throughout later stages as well. Together with recent advances in image processing methods, the analysis of prospective studies as well as existing datasets will help shed further light on the underlying pathophysiological changes within the CP. Such studies are needed to better understand if the CP may represent a novel therapeutic target to ultimately impact the evolution of the disease.</p>","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":"30 5_suppl","pages":"24-29"},"PeriodicalIF":4.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142807543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Selecting Informative Patients for Phase 2 Progressive Trials in MS: Design Considerations for Phase 2 Clinical Trials in Progressive MS.","authors":"Marcus W Koch, Carlos Camara-Lemarroy, Eva Strijbis, Jop Mostert, Victoria M Leavitt, Pavle Repovic, James D Bowen, Jacynthe Comtois, Bernard Uitdehaag, Gary Cutter","doi":"10.1177/13524585241274620","DOIUrl":"10.1177/13524585241274620","url":null,"abstract":"<p><p>While relapsing-remitting multiple sclerosis (MS) has many therapeutic options, progressive forms of MS remain largely untreatable. Phase 2 clinical trials are our main tool to advance new treatments for progressive MS. Given the complexities of progressive MS, it will likely require many phase 2 trials to improve its treatment. To conduct informative and efficient phase 2 trials, it is important that such trials are designed in a way that they can identify a successful treatment as quickly and with as few participants as possible. In this topical review, we discuss cohort selection, outcome selection, cohort enrichment, and dosing selection as strategies to optimize the efficiency of phase 2 clinical trials in progressive MS.</p>","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"41-47"},"PeriodicalIF":4.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11633076/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142154649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging MRI biomarkers for the diagnosis of multiple sclerosis.","authors":"Pietro Maggi, Martina Absinta","doi":"10.1177/13524585241293579","DOIUrl":"10.1177/13524585241293579","url":null,"abstract":"<p><p>The need to improve diagnostic precision in multiple sclerosis (MS) is widely recognized. In recent years, several novel magnetic resonance imaging (MRI) biomarkers have been proposed to enhance diagnostic specificity and reduce misdiagnosis. Some of these imaging biomarkers are deemed highly specific for MS and are likely ready to enter the MS diagnostic work-up, while others are still in their exploratory phase. In addition, new synthetic MRI contrasts and artificial intelligence-based diagnostic algorithms are being tested to reduce the time burden related to imaging data acquisition and analysis. In this review, we summarize the most recent advancement in the field, focusing on the adoption of these novel MRI biomarkers-whether used alone or in combination-for the differential diagnosis of MS.</p>","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"1704-1713"},"PeriodicalIF":4.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142604740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phenotyping <i>in vivo</i> chronic inflammation in multiple sclerosis by combined ¹¹C-PBR28 MR-PET and 7T susceptibility-weighted imaging.","authors":"Constantina A Treaba, Elena Herranz, Valeria T Barletta, Ambica Mehndiratta, Jacob A Sloane, Tobias Granberg, Alessandro Miscioscia, Roberto Bomprezzi, Marco L Loggia, Caterina Mainero","doi":"10.1177/13524585241284157","DOIUrl":"10.1177/13524585241284157","url":null,"abstract":"<p><strong>Background: </strong>¹¹C-PBR28 positron emission tomography (PET), targeting the translocator protein, and paramagnetic rim lesions (PRL) have emerged as promising imaging markers of MS chronic inflammation. No consensus on which is the optimal marker exists.</p><p><strong>Objectives: </strong>To investigate the ability of ¹¹C-PBR28 PET and PRL assessment to identify chronic inflammation in white matter (WM) MS lesions and their relation to neurological impairment.</p><p><strong>Methods: </strong>Based on ¹¹C-PBR28 uptake, brain WM lesions from 30 MS patients were classified as PET active or inactive. The PRL presence was assessed on 7T phase reconstructions, T1/T2 ratio was calculated to measure WM microstructural integrity.</p><p><strong>Results: </strong>Less than half (44%) of non-PRL WM lesions were active on ¹¹C-PBR28 imaging either throughout the lesion (whole active) or at its periphery. PET peripherally active lesions and PRL did not differ in T1/T2 ratio and ¹¹C-PBR28 uptake. A positive correlation was observed between PRL and active PET lesion count. Whole active PET lesion volume was the strongest predictor (β = 0.97, <i>p</i> < 0.001) of increased Expanded Disability Status Scale scores.</p><p><strong>Conclusion: </strong>¹¹C-PBR28 imaging reveals more active WM lesions than 7T PRL assessment. Although PRL and PET active lesion counts are related, neurological disability is better explained by PET whole active lesion volume.</p>","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"1755-1764"},"PeriodicalIF":4.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11742271/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142504424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relapsing tumefactive demyelination: time to recognize a distinct demyelinating condition?","authors":"Todd A Hardy, Brian G Weinshenker","doi":"10.1177/13524585241273075","DOIUrl":"10.1177/13524585241273075","url":null,"abstract":"","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"1838-1839"},"PeriodicalIF":4.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142154648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Secondary organising pneumonia associated to COVID-19 infection in patients with central nervous system inflammatory demyelinating diseases treated with anti-CD20 therapies.","authors":"René Carvajal, Breogán Rodríguez-Acevedo, Lorena García-Vasco, Ana Zabalza, Helena Ariño, Luca Bollo, Noemí Cabello-Clotet, Joaquín Castilló, Álvaro Cobo-Calvo, Manuel Comabella, Anna Falcó-Roget, Ingrid Galán, Alexis García-Sarreón, Irene Gómez-Estévez, Galo Granados, Delon La Puma, Gloria Mato Chain, Luciana Midaglia, Asunción Nieto-García, Susana Otero-Romero, Agustín Pappolla, Marta Rodriguez, Irene Sansano, Jordi Río, Paula Tagliani, Carmen Tur, Ángela Vidal-Jordana, Andreu Vilaseca, Ana Villar, Jaume Sastre-Garriga, Celia Oreja-Guevara, Mar Tintoré, Xavier Montalban, Georgina Arrambide","doi":"10.1177/13524585241297038","DOIUrl":"10.1177/13524585241297038","url":null,"abstract":"<p><strong>Background: </strong>Organizing pneumonia (OP), an interstitial lung disease, has been observed in patients with inflammatory demyelinating diseases (IDDs) treated with anti-CD20, particularly after COVID-19, but data are limited.</p><p><strong>Aim: </strong>To provide a detailed characterization of COVID-19-associated OP in IDD patients treated with anti-CD20.</p><p><strong>Methods: </strong>Bi-centric retrospective cohort study including patients with multiple sclerosis (MS), aquaporin-4-positive neuromyelitis optica spectrum disorder (AQP4 + NMOSD), and myelin oligodendrocyte glycoprotein antibody disease (MOGAD) who received anti-CD20 and were diagnosed with COVID-19-associated OP between March 2020 and October 2023.</p><p><strong>Results: </strong>Nineteen patients were included (mean age 46.8 years; 52.6% female; 63% rituximab, 37% ocrelizumab). Sixteen had MS, two MOGAD, and one AQP4 + NMOSD. Intermittent fever was the predominant symptom. Hospitalization occurred in all but one patient, without fatalities. Chest CT consistently showed OP patterns. Thirteen patients had positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) PCR in bronchoalveolar lavage. Treatments included corticosteroids, antivirals, monoclonal antibodies, and convalescent plasma. Fourteen patients postponed infusions; nine resumed post-recovery (median 11.9 months), two switched due to hypogammaglobulinemia, and three stopped. After a mean follow-up of 1.5 years, lung abnormalities and clinical manifestations resolved in 18 patients; however, 13 experienced long-COVID.</p><p><strong>Conclusions: </strong>In anti-CD20-treated patients with recurrent fever and distinctive CT features, COVID-19-associated OP should be considered.</p>","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"1788-1801"},"PeriodicalIF":4.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142624290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiple sclerosis and cancer: Navigating a dual diagnosis.","authors":"Cassie Nesbitt, Anneke Van Der Walt, Helmut Butzkueven, Bianca Devitt, Vilija G Jokubaitis","doi":"10.1177/13524585241274523","DOIUrl":"10.1177/13524585241274523","url":null,"abstract":"<p><p>Healthcare breakthroughs are extending the lives of multiple sclerosis (MS) patients and cancer survivors, creating a growing cohort of individuals navigating a dual diagnosis. Determining the relationship between MS and cancer risk remains challenging, with inconclusive findings confounded by age, risk exposures, comorbidities, genetics and the ongoing introduction of new MS disease-modifying therapies (DMTs) across study periods.This research places significant emphasis on cancer survival, with less attention given to the impact on MS outcomes. Our review explores the existing literature on MS, cancer risk and the intersection of DMTs and cancer treatments. We aim to navigate the complexities of managing MS in cancer survivors to optimise outcomes for both conditions. Continuous research and the formulation of treatment guidelines are essential for guiding future care. Collaboration between neuro-immunology and oncology is crucial, with a need to establish databases for retrospective and ultimately prospective analysis of outcomes in these rapidly evolving fields.</p>","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"1714-1736"},"PeriodicalIF":4.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142350378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relapsing tumefactive demyelination lesions: A unique, distinct inflammatory brain pathology.","authors":"Paola Perini, Marta Gaggiola, Francesca Rinaldi, Paolo Gallo, Marco Puthenparampil","doi":"10.1177/13524585241273005","DOIUrl":"10.1177/13524585241273005","url":null,"abstract":"<p><p>We report the case of a patient suffering from biopsy-proven relapsing tumefactive demyelinating lesions (TDLs) of the central nervous system who had five relapses in 16 years. No signs/symptoms suggestive of alternative pathologies emerged during the follow-up. A limited benefit was observed with intravenous (IV) high-dose steroids, while both plasma exchange and IV immunoglobulin G (IgG) administration were ineffective. A long-lasting (9 years) but transient clinical stabilization was obtained with cyclophosphamide. Our case supports the view that recurrent TDL is a relapsing brain inflammation not belonging to multiple sclerosis (MS) or myelin oligodendrocyte glycoprotein (MOG)-/AQP4-associated disorders. TDL concept and clinical features should be revised.</p>","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"1835-1838"},"PeriodicalIF":4.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142154647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Choroid Plexus as a Mediator of CNS Inflammation in Multiple Sclerosis.","authors":"Alexandra Hochstetler, Maria K Lehtinen","doi":"10.1177/13524585241292974","DOIUrl":"10.1177/13524585241292974","url":null,"abstract":"<p><p>The pathophysiology of multiple sclerosis (MS) remains poorly understood despite decades of tremendous research efforts. Advances in neuroradiography coupled with availability of unbiased approaches including spatial transcriptomics, proteomics, metabolomics, and lipidomics that are compatible with brain and fluid specimens from patients raise hope that discovery of novel disease drivers is on the horizon. Once thought to be little more than salty bathwater, our modern understanding of cerebrospinal fluid (CSF) suggests the CSF as a compelling, critical regulator of brain function in health and disease. Recent studies in the field have reinvigorated interest in CSF as a medium to better understand MS and to deliver disease-modifying therapies. In turn, the choroid plexus, an epithelial tissue located within each brain ventricle that regulates CSF and forms a key blood-CSF barrier, is uniquely positioned to orchestrate neuroinflammation associated with MS. In this perspective review, we will discuss what is known about the choroid plexus as a conductor of immune responses and how it may propagate neuroinflammation associated with MS via the CSF.</p>","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"19-23"},"PeriodicalIF":4.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11634642/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}